Key result
Oral anticoagulation is linked to ~70% lower 30-day mortality vs no anticoagulation in AF and AKI.
Why the study?
Does oral anticoagulation therapy reduce 30-day mortality in patients with acute kidney injury and concomitant atrial fibrillation?
Observational (n=19,672)
Does oral anticoagulation therapy reduce 30-day mortality in patients with acute kidney injury and concomitant atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Oral anticoagulation administration is associated with significantly improved 30-day survival in patients with acute kidney injury and concomitant atrial fibrillation.
OBJECTIVE: A retrospective study. SETTING: This study was conducted in the Medical Information Mart for Intensive Care IV database. PARTICIPANTS: A total of 19 672 patients diagnosed with AKI. MAIN OUTCOME MEASURES: Patients were categorised into three groups: (1) AF; (2) AKI and AF, OAC-; (3) AKI and AF, OAC+. The primary endpoint was 30-day mortality. Secondary endpoints were the length of stay (LOS) in the intensive care unit (ICU) and hospital. Propensity score matching (PSM) and Cox proportional hazards model adjusted confounding factors. Linear regression was applied to assess the associations between OAC treatment and LOS. RESULTS: After PSM, 2042 pairs of AKI and AF patients were matched between the patients who received OAC and those without anticoagulant treatment. Cox regression analysis showed that, OAC significantly reduce 30-day mortality compared with non-OAC (HR 0.30; 95% CI 0.25 to 0.35; p<0.001). Linear regression analysis revealed that OAC prolong LOS in hospital (11.3 days vs 10.0 days; p=0.013) and ICU (4.9 days vs 4.4 days; p<0.001). OAC did not improve survival in patients with haemorrhage (HR 0.67; 95% CI 0.34 to 1.29; p=0.23). Novel OAC did not reduce mortality in acute-on-chronic renal injury (HR 2.03; 95% CI 1.09 to 3.78; p=0.025) patients compared with warfarin. CONCLUSION: OAC administration was associated with improved short-term survival in AKI patients concomitant with AF.
No takes yet. Share an insight, caveat, or question.
Bo et al. (2023) conducted an observational in Acute kidney injury with atrial fibrillation (n=19,672). Oral anticoagulation therapy (OAC) vs. No anticoagulant treatment (non-OAC) was evaluated on 30-day mortality (HR 0.30, 95% CI 0.25 to 0.35, p=<0.001). Oral anticoagulation reduced 30-day mortality compared with no anticoagulation in patients with acute kidney injury and atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: